French health authorities have approved the use of an anti-body treatment made by AstraZeneca for high-risk people who show resistance to vaccines against coronavirus, reports AFP.
The independent public health body, HAS, announced “a green light for the preventive use of Evusheld ... for patients with a very high-risk of contracting a severe form of Covid-19”.
Evusheld, developed by the British-Swedish pharma company, this week received emergency use authorisation in the US for adults and children aged 12 and above.
The French approval is for adults only.
